Results by Type
News Results 1-10 of 199
Sponsored Links
Affymax receives positive review for Phase III anemia program
News | www.pharmaceutical-business-review.com | Aug 8, 2008
Affymax has received positive review from the independent data monitoring committee, which provides oversight for the Phase III program for Hematide, a synthetic, PEGylated peptidic compound that acts as an erythropoiesis stimulating agent.
Affymax, Inc. Says to Continue Studying Anemia Drug
News | www.biospace.com | Aug 8, 2008
PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY - News) today announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase 3 program for Hematide, has completed its first review of the data and informed the company that the cumulative safety
http://www.biospace.com/news_story.aspx?StoryID=106289&full=1
Assay for serum hepcidin may help diagnose anemia of chronic disease.
News | www.eurekalert.org | Aug 5, 2008
University of Utah School of Medicine researchers have developed a new tool that facilitates diagnosis of anemia related to chronic illness, as well as diseases of iron overload. The results of a study detailing the new tool are published in the August 2008 issue of the journal Cell Metabolism, a
http://www.eurekalert.org/pub_releases/2008-08/uouh-ksi080108.php
FDA: More Label Warnings for Anemia Drugs (at TheStreet.com)
News | www.thestreet.com | Jul 31, 2008
The regulatory agency issues further label revisions for drugs like Amgen's Aranesp and JJ's Procrit.
F.D.A. to Tighten Use of Amgen Anemia Drugs
News | www10.nytimes.com | Jul 30, 2008
The move, which the F.D.A. is expected to announce on Wednesday, represents the first time the agency has ordered changes in a drug’s prescribing information.
AMAG Pharmaceuticals, Inc. Reports Financial Results for the Quarter Ended June 30, 2008 (Business Wire)
News | biz.yahoo.com | Jul 29, 2008
AMAG Pharmaceuticals, Inc. Reports Financial Results for the Quarter Ended June 30, 2008. - CAMBRIDGE, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG - News), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization
Combination of Cancer Drugs Linked to Anemia
News | www.medpagetoday.com | Jul 16, 2008
ROCKVILLE, Md. -- Combining two targeted therapies -- bevacizumab (Avastin) and sunitinib (Sutent) -- may promote microangiopathic hemolytic anemia in patients with solid tumors, according to Genentec
http://www.medpagetoday.com/ProductAlert/Prescriptions/tb/10142
Genentech warns of anemia in Avastin combo trial
News | uk.reuters.com | Jul 14, 2008
WASHINGTON (Reuters) - Genentech Inc has warned doctors about a type of anemia seen in patients treated with the company's blockbuster cancer drug Avastin in combination with Pfizer Inc's Sutent in a clinical
http://uk.reuters.com/article/healthNews/idUKN1446194620080714?feedType=RSS&feedName=healthNews
CORRESPONDENCE: Hydroxyurea for Sickle Cell Anemia
News | content.nejm.org | Jul 2, 2008
Correspondence from The New England Journal of Medicine -- Hydroxyurea for Sickle Cell Anemia
http://content.nejm.org/cgi/content/short/359/1/98?rss=1&query=current
AMAG Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript (at Seeking Alpha)
News | seekingalpha.com | Jun 23, 2008
Good morning. My name is Laurie and I will be your conference operator. At this time I would like to welcome everyone to the AMAG first quarter financial results conference call. All lines have been placed on mute to prevent any background noise.
Or copy the embed script code below and paste it on your website:
Embed code:
>
